Edwards Lifesciences price target raised to $95 from $82 at RBC Capital

RBC Capital raised the firm’s price target on Edwards Lifesciences to $95 from $82 and keeps an Outperform rating on the shares. The company’s Q4 results topped estimates as TAVR sales beat expectations, and the management’s 2024 guide of 8%-10% “looks achievable” with room for upside, the analyst tells investors in a research note. RBC adds that its price target increase reflects the recent run-up in the stock price.